Our group investigates the interaction between tumor cells and the host immune system, with emphasis on the development of new immunotherapeutic strategies. In particular, we are developing a novel strategy of active immunotherapy based on the delivering of tumor antigens to anatomic sites where immune responses occur, i.e.: lymph nodes. Moreover, we are investigating the way tumors escape immune surveillance. In this context, we have recently identified a novel pathway of immune evasion adopted by tumors of different histological type, which relies on the inhibition of the chemokine receptor CCR7 on dendritic cells undergoing activation. The inhibition of CCR7 expression hampers dendritic cell migration to lymph nodes, thus dampening the antitumor immune response.